BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 8647757)

  • 1. Comparative in-vitro activity of sparfloxacin and eight other antimicrobial agents against clinical isolates of non-tuberculous mycobacteria.
    Sánchez-Carrillo C; Cotarelo M; Cercenado E; Vicente T; Blázquez R; Bouza E
    J Antimicrob Chemother; 1996 Jan; 37(1):151-4. PubMed ID: 8647757
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Evaluation of Antimicrobial Susceptibilities of Rapidly Growing Mycobacteria].
    Özkarataş MH; Arslan N; Esen N; Özkütük AA
    Mikrobiyol Bul; 2023 Apr; 57(2):220-237. PubMed ID: 37067207
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In-vitro activity of quinolones and macrolides against mycobacteria.
    Yew WW; Piddock LJ; Li MS; Lyon D; Chan CY; Cheng AF
    J Antimicrob Chemother; 1994 Sep; 34(3):343-51. PubMed ID: 7829409
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Comparison of in vitro antimicrobial activities of ofloxacin, levofloxacin, ciprofloxacin, and sparfloxacin against various mycobacteria].
    Kawahara S; Tada A; Nagare H
    Kekkaku; 2001 Apr; 76(4):357-62. PubMed ID: 11398326
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In Vitro Antimicrobial Susceptibility of Nontuberculous Mycobacteria in Iran.
    Heidarieh P; Mirsaeidi M; Hashemzadeh M; Feizabadi MM; Bostanabad SZ; Nobar MG; Hashemi Shahraki A
    Microb Drug Resist; 2016 Mar; 22(2):172-8. PubMed ID: 26468990
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro activity of ciprofloxacin, sparfloxacin, ofloxacin, amikacin and rifampicin against Ghanaian isolates of Mycobacterium ulcerans.
    Thangaraj HS; Adjei O; Allen BW; Portaels F; Evans MR; Banerjee DK; Wansbrough-Jones MH
    J Antimicrob Chemother; 2000 Feb; 45(2):231-3. PubMed ID: 10660507
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro activity of quinolones and other antimicrobial agents against anaerobic bacteria.
    Nord CE
    Clin Infect Dis; 1996 Dec; 23 Suppl 1():S15-8. PubMed ID: 8953101
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative in-vitro activities of the new quinolone, Bay y 3118, and ciprofloxacin, sparfloxacin, tosufloxacin, CI-960 and CI-990.
    Bauernfeind A
    J Antimicrob Chemother; 1993 Apr; 31(4):505-22. PubMed ID: 7605398
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [In vitro activity of sparfloxacin against methicillin-resistant staphylococci].
    Wallrauch C; Voss A; Milatovic D; Braveny I
    Arzneimittelforschung; 1995 Jun; 45(6):723-5. PubMed ID: 7646580
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Bactericidal activity of ciprofloxacin and sparfloxacin. Comparison with others active antibiotics against Pasteurella multocida].
    Gastine C; Donnio PY; Travert MF; Avril JL
    Presse Med; 1995 Mar; 24(11):519-22. PubMed ID: 7770389
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro activity of sparfloxacin and other antimicrobial agents against genital pathogens.
    Lefèvre JC; Bauriaud R; Gaubert E; Escaffre MC; Lareng MB
    Chemotherapy; 1992; 38(5):303-7. PubMed ID: 1337506
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro activity of sparfloxacin compared with ciprofloxacin and ofloxacin against respiratory tract pathogens.
    Malmborg AS; Ahlén S
    Chemotherapy; 1993; 39(1):32-5. PubMed ID: 8383030
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activity of quinolones against mycobacteria.
    Jacobs MR
    Drugs; 1995; 49 Suppl 2():67-75. PubMed ID: 8549419
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activity of quinolones against mycobacteria.
    Jacobs MR
    Drugs; 1999; 58 Suppl 2():19-22. PubMed ID: 10553700
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative antimycobacterial activities of difloxacin, temafloxacin, enoxacin, pefloxacin, reference fluoroquinolones, and a new macrolide, clarithromycin.
    Gorzynski EA; Gutman SI; Allen W
    Antimicrob Agents Chemother; 1989 Apr; 33(4):591-2. PubMed ID: 2524998
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In-vitro activity of sparfloxacin, a new quinolone antimicrobial agent.
    Cooper MA; Andrews JM; Ashby JP; Matthews RS; Wise R
    J Antimicrob Chemother; 1990 Nov; 26(5):667-76. PubMed ID: 2079449
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of antimicrobial susceptibilities of rapidly growing mycobacteria by Sensititre RAPMYCO panel.
    Cavusoglu C; Gurpinar T; Ecemis T
    New Microbiol; 2012 Jan; 35(1):73-6. PubMed ID: 22378556
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Drug sensitivity analysis of Mycobacterium chelonae and Mycobacterium abscessus and evaluation of Etest for susceptibility testing].
    Gui J; Wang F; Hong CY; Li JL; Liang J
    Zhonghua Jie He He Hu Xi Za Zhi; 2013 Aug; 36(8):567-71. PubMed ID: 24252731
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preliminary study of the in vitro activity of irloxacin against mycobacteria.
    Casal M; Gutierrez J; Ruiz P; Moreno G
    Chemotherapy; 1995; 41(3):204-7. PubMed ID: 7656667
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative in-vitro susceptibilities of Pseudomonas aeruginosa, Xanthomonas maltophilia, and Pseudomonas spp. to sparfloxacin (CI-978, AT-4140, PD131501) and reference antimicrobial agents.
    Louie A; Baltch AL; Ritz WJ; Smith RP
    J Antimicrob Chemother; 1991 Jun; 27(6):793-9. PubMed ID: 1657857
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.